tbuckley/cabot-search huggingface dataset:
Poster No. 054 Genetic variation in the TCF21 gene is associated with the severity of coronary artery disease
Authors: Débora Sá, M I Mendonça, M Santos, M Temtem, A C Sousa, M Rodrigues, E Henriques, S Freitas, S Borges, G Guerra, A I Freitas, I Ornelas, A Drumond, R Palma Dos Reis
Journal: Cardiovascular Research (2022)

Abstract Introduction In vitro studies demonstrated that targeted deletion of the transcription factor encoding gene TCF21, was associated with vascular smooth muscle cell disruption. Recent research showed that TCF21 expression contribute to fibrous cap formation, preventing heart attacks. Purpose Analyse the TCF21 rs12190287 gene and evaluate its association with atherosclerosis severity measured according to the coronary angiogram patients´ data. Methods: Prospective study with 1,639 coronary artery disease (CAD) patients (mean age 53.4 ± 7.8 years). Two age groups (&amp;lt; 55 and &amp;gt; 55 years) were stratified and analyzed. TCF21 rs12190287 G &amp;gt; C was genotyped in all patients. The severity of CAD was graded according to the number of obstructed coronary arteries with at least 70% narrowed lumen. Chi-squared tests and multivariate logistic regression models were analysed. Results The CC genotype was associated with &amp;gt; 70% obstructive lesions (vascular disease rate, 48.1%). Contrariwise, the GG wild genotype was associated with less severe obstructive disease (19.5%) (P = 0.003). When we stratified the TCF21 genotypes per age group (55 years), the CC genotype in the younger group had more obstructed disease (47.4%) when compared with GG (18.8%) (P = 0.012), but this effect was not significant in the older group. Multivariate analysis (logistic regression) showed that the CC genotype had a high risk of multivessel coronary disease (OR = 2.88; P = 0.001) than GG. Conclusion This work shows that the TCF21 wild genotype protects against CAD severity. In contrast, the CC genotype is associated with an increased risk of CAD severity.
Poster No. 047 A comparative study of high-intensity statin therapy in post-acute coronary syndrome patients undergoing a cardiac rehabilitation program
Authors: Margarida Cabral, Mariana Carvalho, Rita Santos, José Bernardo Ferreira, Catarina Ruivo, Filipa Januário, Alexandre Antunes, João Morais
Journal: Cardiovascular Research (2022)

Abstract Aggressive lipid lowering has been shown to be a crucial part of secondary prevention after acute coronary syndrome (ACS). The selection of the best lipid-lowering agents is controversial, with some trials showing rosuvastatin as more efficacious in improving lipid profile compared to atorvastatin, others showing no difference. Another concern is the impact of statin therapy on the reduction of muscle oxidative capacity, and, consequently, on functional capacity. This study aimed to analyse the differences in lipid profile and physical capacity in post-ACS patients undergoing a cardiac rehabilitation program (CPR), medicated with rosuvastatin versus atorvastatin. A retrospective analysis of patients in phase 2 of CRP between 2017 and 2020 was performed. Two groups were created: group 1 for patients under atorvastatin 40 mg and group 2 under rosuvastatin 20 mg. Variables were analysed at the beginning and the end of phase 2, 12 weeks later. A P-value &amp;lt; 0.05 is statistically significant. A total of 98 patients completed phase 2 of CRP, of which 14 are part of group 1, 67 of group 2, and 17 users of other lipid-lowering drugs. Table 1 shows the main characteristics. Univariate (table 2) and multivariate analyses show no differences regarding lipid profile or functional activity between groups. In conclusion, in this group of patients, high-intensity rosuvastatin and atorvastatin in secondary prevention post-ACS had a comparable impact on lipidic profile, without a significant difference in functional activity, independently of age, sex or comorbidities. Larger randomized prospective trials, including phase 3 of CRP, are needed to confirm these results.
Retracted: Poster No. 092 The impact of pre-existing right bundle brunch block on short and mid-term outcomes after transcatheter aortic valve implantation
Authors: Mariana Ribeiro Silva, Gualter Santos Silva, Pedro Ribeiro Queirós, Mariana Brandão, Diogo Santos-Ferreira, Cláudio Guerreiro, Marco Oliveira, Helena Gonçalves, João Primo, Gustavo Pires-Morais, Bruno Melica, Lino Santos, Alberto Rodrigues, Pedro Braga, Ricardo Fontes-Carvalho
Journal: Cardiovascular Research (2022)

This abstract has been withdrawn. Please see: https://doi.org/10.1093/cvr/cvac183
Oral Presentation No. 32 The interplay between VWF, ADAMTS13 and TSP1, and their relation to clinical endpoints
Authors: Ellen Mathea Kirsch Warlo, Are A Kalstad, Peder L Myhre, Svein Solheim, Harald Arnesen, Arnljot Tveit, Ingebjørg Seljeflot, Vibeke Bratseth
Journal: Cardiovascular Research (2022)

Abstract Introduction ADAMTS13 cleaves von Willebrand Factor (VWF) into less active fragments. TSP1 binds to VWFs cleavage-site, protecting it from degradation. Low ADAMTS13 and high VWF have been associated with cardiovascular disease (CVD) and atrial fibrillation (AF). We aimed to investigate the interplay between VWF, ADAMTS13 and TSP1, and assess any relation to endpoints. Materials and methods 1027 elderly with a recent myocardial infarction (MI) were followed for 2 years. ADAMTS13 antigen (ag) and activity (act), VWF ag and TSP1 were analyzed. The primary endpoint (MACE; n = 210) included MI, stroke, heart failure hospitalization, coronary revascularization and death. The secondary endpoint was new-onset AF (n = 43). Results ADAMTS13 ag and act were weakly correlated to VWF (r = 0.10, P = 0.002, both). TSP1 did not correlate to ADAMTS13 or VWF. Patients experiencing a MACE had higher VWF and lower ADAMTS13(ag) at baseline (P &amp;lt; 0.012, both), however not significant after adjusting for covariates. The association with MACE was mainly driven by death (n = 40), with an adjusted OR 2.4 (P = 0.008) for VWF Q4 vs. Q1-3 and OR 0.4 (P = 0.012) for ADAMTS13(ag) Q1 vs. Q2-4. VWF was lower (1.25 vs. 1.39 IU/mL, P = 0.008) and VWF/ADAMTS13(ag)-ratio was lower (1.81 vs. 2.05 x10−3, P = 0.009) in patients with new-onset AF, and these associations persisted in adjusted models. Conclusion In elderly patients with a recent MI, levels of VWF, ADAMTS13 and TSP1 did not correlate. ADAMTS13 and VWF associated weakly with MACE, mainly driven by death. Low VWF and VWF/ADAMTS13-ratio were associated with new-onset AF in our population and needs further research.
Oral Presentation No. 126 NOACs safety and efficacy in Adult Congenital Heart Disease
Authors: Ricardo Jorge Reis Alves Pinto, Miguel Martins Carvalho, Tânia Proença, Catarina Costa, Ana Filipa Amador, João Calvão, Catarina Marques, André Cabrita, Luís Santos, Cátia Oliveira, Ana Pinho, Cristina Cruz, Filipe Macedo
Journal: Cardiovascular Research (2022)

Abstract Introduction Adult Congenital Heart Disease(ACHD) patients are an increasing population with known high risk for thromboembolic events.Validated scores are uncertain in this population. Although apparently safe, data is scarce about the use of NOAC. Purpose To evaluate all patients on-NOAC followed in an ACHD outpatients clinic and observe its safety and efficacy during a median follow-up of 34 months (IQR 7–60 months). Major bleeding was defined according to types 3 to 5 in BARC scale. Adverse event was defined as ≥ 1 of the follows: death, stroke, myocardial infarction, systemic embolism or major bleeding. Results A total of 65 patients were included, with a mean age of 52 ± 14 year-old, 66% female. Most frequent ACHD were atrial septal defect (22%) and tetralogy of Fallot (22%), followed by atrioventricular septal defect (17%) and transposition of great arteries (9%). Most patients had preserved biventricular function, 20% presented systemic ventricle systolic dysfunction and 12% subpulmonic ventricle systolic dysfunction. Atrial fibrillation or atrial flutter (AF/AFL) were the major reasons for anticoagulation (94%); the remaining were on NOAC due to previous ischaemic stroke, intra-cardiac thrombus or deep venous thrombosis. At the time of NOAC initiation, 49% had a CHA2DS2-VASc score ≥ 2 (median 1, IQR 1-3) and median HAS-BLED score was 0 (IQR 0-2);43% were medicated with apixaban, 29% with rivaroxaban,22% with edoxaban and 6% with dabigatran.During a median follow-up of 34 months, none had ischaemic complications or major bleeding and one patient died after pulmonic prothesis dysfunction surgery. Concerning time-to- adverse-event analysis, all patients kept uneventful after 2 years and more than 95% continued event-free after 8 years on-NOAC.
Oral Presentation No. 69 Chronotropic incompetence: still a suitable indicator?
Authors: Isabel Cruz, Inês Oliveira, Bruno Bragança, Rafaela Lopes, Rui Santos, Conceição Queirós, Aurora Andrade
Journal: Cardiovascular Research (2022)

Abstract Background Chronotropic incompetence (CI) is defined as the inability to increase heart rate (HR) in response to increased activity. It is common in patients (pts) with cardiovascular (CV) disease, being a predictor of major adverse CV events; however, its importance is often underestimated in clinical practice. Purpose Evaluate the prognostic value of CI in pts with known coronary artery disease (CAD) who performed Bruce protocol treadmill testing. Methods Unicentric, retrospective analysis of consecutive pts with known CAD who underwent Bruce protocol treadmill testing between 2009 and 2010. Chronotropic index (ChI) was calculated as:(peak HR–resting HR)/(220–age–resting HR). CI was defined as ChI &amp;lt; 80% (&amp;lt; 62% in pts prescribed with beta-blockers). Pts were divided in two groups-G1: CI and G2: normal chronotropic response. Events were defined as: de novo heart failure (HF), CAD progression, myocardial infarction (MI), stroke, all-cause mortality and CV mortality. Results A total of 471 pts were included (87.3% male, mean age 69 ± 9.8 years). Mean follow-up was 9.7 years. The groups were similar regarding sex, age, body mass index, diabetes, arterial hypertension, dyslipidemia, MI and left ventricle ejection fraction (P &amp;gt; 0.050). CI was identified in 27.4% pts. Comparing G1 vs. G2, no differences were found related to all-cause mortality, de novo HF, CAD progression, MI and stroke (P &amp;gt; 0.050). However, statistically significant differences were found regarding CV mortality (P = 0.028). Conclusion CI is a simple an easily available parameter that shows a clear association with CV mortality in a long-term follow-up of pts with CAD.
Retracted: Poster No. 021 Correlation of Inflammation and Coagulation Serum Markers with The Incidenceof Deep Vein Thrombosis in High-Risk Thrombosis Cancer Patients
Authors: Widi Budianto, Budi Setiawan
Journal: Cardiovascular Research (2022)

This abstract has been withdrawn. Please see: https://doi.org/10.1093/cvr/cvac183
Poster No. 013 Development of Small and Wide Angle X-ray Scattering to Investigate the Stability of Atherosclerotic Plaque
Authors: Rebecca Mackley, Tara Schiller
Journal: Cardiovascular Research (2022)

Abstract Atherosclerosis is often described as a single disease entity however the size and composition of each plaque is unique to the individual. Thus, the field currently lacks a technique that can discriminate stable form unstable plaques to identify those being at risk of suffering a thromboembolic event in the near future. There exists a perfect opportunity to develop a non-invasive imaging technique or device that would be able to discriminate between different plaques at multiple locations in an artery. Such a device requires extensive chemical, structural, and spatial information available on the different plaque components to define the stability of the plaque. With informed consent and approved ethics, human carotid endarterectomy specimens were collected, fixed and mounted in Kapton tape, which is an ideal substrate for use with x-rays. Small-angle x-ray scattering was used to gather information on the size, shape and structure of the constituents of a plaque such as collagen and lipid-based materials. Then wide-angle x-ray scattering was used to readily determine the crystalline materials such as crystalline cholesterol and hydroxyapatite. Results currently indicate that this technique can discriminate between crystalline cholesterol, cholesteryl esters, phospholipids, collagen, elastin, hydroxyapatite and other calcium-based salts. This technique can map across the face of the plaque indicating the co-location of materials. In particular, for the crystalline materials, the crystalline planes can be indexed showing how the material grows in the plaque. Relating this information back to patient data can help identify features of a vulnerable plaque. Funding sources Medical Research Council, UK.
Oral Presentation No. 079 Quality of life in patients after pulmonary embolism. Correlation with echocardiographic and biochemical parameters
Authors: O L Kardakari, C H Ballas, L A Lakkas, S O Giannou, I L Stamou, I O Samara, P E Kalogeras, K O Siaravas, E F Papaioannou, B A Mpouratzis, S P Sioros, E K Lambrinou, G E Dimakopoulos, A T H Konstantinidis, K K Naka, L K Michalis, C S Katsouras
Journal: Cardiovascular Research (2022)

Abstract Background Pulmonary embolism (PE) is the third most common cause of cardiovascular death worldwide, after stroke and heart attack. Our purpose was to evaluate the patient's health-related quality of life (HR-QoL) after Acute Pulmonary Embolism (APE) and its association with biochemical and novel echocardiographic parameters of assessment of right ventricle (RV). Material and methods Successive patients with diagnosis of APE in a tertiary hospital were included in the study. RV evaluation and biochemical markers, (including Brain Natriuretic Peptide (BNP)) were recorded during hospitalization. HR-QoL was evaluated with the Greek version of the Pulmonary Embolism Quality of Life questionnaire (PEmb-Qol), at 1 and 3 months after the APE. Repeated measures analysis was used to assess changes in the PEmb-QoL dimensions and Pearson correlations to assess the relationships between RV global longitudinal strain (RV GLS) and the dimensions of Pemb-Qol. Results and conclusions One hundred consecutive patients were screened; 14 patients were excluded. The study sample consisted of 86 individuals (47 women) aged 69.7 ± 13.4 (mean ± SD) years. The differences between the two time points were statistically significant (P &amp;lt; 0.001) in all dimensions of HR-QoL. At 3 months, the dimensions of social limitations and intensity of complaints showed the highest rate of improvement. RV GLS values were correlated with quality of life in patient with APE (in 3 of the 6 dimensions of Pemb-Qol). While BNP, was related to the “intensity of complaints” dimension of Pemb-Qol,in patients with APE occurred during hospitalization for another reason (PE wasn't the cause of admission).
Retracted: Poster No. 005 Platelet Thromboxane Inhibition by Low-Dose Aspirin in Polycythemia Vera:Ex Vivo and In Vivo Measurements and In Silico Simulation
Authors: Giovanna Petrucci, Alberto Giaretta, Paola Ranalli, Viviana Cavalca, Alfredo Dragani, Benedetta Porro, Duaa Hatem, Aida Habib, Elena Tremoli, Carlo Patrono, Bianca Rocca
Journal: Cardiovascular Research (2022)

This abstract has been withdrawn. Please see: https://doi.org/10.1093/cvr/cvac183
Oral Presentation No. 56 Elevated White Blood Cells Count and C-Reactive Protein as markers for coronary heart disease prognosis
Authors: Débora Sá, Maria Isabel Mendonça, Marina Santos, Margarida Temtem, Ana Célia Sousa, Mariana Rodrigues, Eva Henriques, Sónia Freitas, Sofia Borges, Ilídio Ornelas, António Drumond, Roberto Palma Dos Reis
Journal: Cardiovascular Research (2022)

Abstract Background White blood count (WBC) and C-reactive protein (CRP) elevation are well-recognized inflammation indicators and considered risk factors for coronary heart disease (CHD). Most of the other newly introduced inflammatory risk markers are expensive to test, are not readily available, lack standardization, and have not been confirmed by multiple prospective studies. Whether these classic inflammatory markers may predict majoradverse coronary events (MACE) in CHD patients is controversial. We aimed to evaluate whether high WBC and CRP are independent risk factors for MACE occurrence in CHD patients with an extended follow-up. Material and methods A cohort of 1,713 CHD patients (mean age 54.0 ± 7.5 years, 78.6% male) was prospectively followed during an extended time of 4.9 ± 3.4 years (range 1 to 17 years). Bivariate and multivariate Cox regression with WBC, CRP and traditional risk factors (age,gender, smoking, family history, dyslipidemia, diabetesand BMI) analyzed those significantlyassociated with MACE. Results and conclusions MACE group presented a higher percentage of non-smokers (P = 0.006); hypertension (P = 0.003); dyslipidemia (P = 0.025) and diabetes (P &amp;lt; 0.0001). WBC (P = 0.048) and CRP (P &amp;lt; 0.0001) were also significantly higher in patients with MACE relatively to non-MACE patients. After multivariate Cox analysis, WBC and CRP remained significant risk factors for MACE, with diabetes and hypertension presenting as strong statistical value. As a conclution, the inflammatory CRP and WBC factors are accurate to predict MACE in secondary prevention. These biomarkersare easily accessed, providing helpful information in the prognosis of cardiovascular patients.
Oral Presentation No. 84 Initial clinical experience with 6-hour enoxaparin regimen in opiate-treated patients undergoing primary percutaneous coronary intervention
Authors: Nadir Elamin, Kok Weng Ow, William A E Parker, Thomas A Nelson, Janet Middle, Jessica Hanson, Bethany Moyle, Arvindra Krishnamurthy, David Barmby, Kenneth Morgan, Zulfiquar Adam, Alexander Rothman, Paul Morris, Javaid Iqbal, Ian Hall, Dwayne Conway, James Richardson, Julian P Gunn, Robert F Storey
Journal: Cardiovascular Research (2022)

Abstract Background Opioid treatment delays the onset of oral P2Y12 inhibitors in patients with acute ST-segment elevation myocardial infarction (STEMI), leading to suboptimal antithrombotic therapy during primary percutaneous coronary intervention (PPCI). Material and methods We retrospectively compared using a prolonged enoxaparin regimen (0.75 mg/kg bolus followed by 6-hour intravenous infusion) to using unfractionated heparin (UFH) with or without tirofiban in opioid-treated patients with STEMI who underwent PPCI. We compared the proportions of acute stent thrombosis (AST) and bleeding events according to the bleeding academic research consortium (BARC) within 24 hours post-PPCI. Results 270 opioid-treated patients with a mean age of 63 [SD ± 12] years were enrolled, of which 49 (18%) were with diabetes mellitus (DM). 90 (34%) patients (mean age 61 [SD ± 11] years) received enoxaparin, 110 (41%) (mean age 65 [SD ± 14] years) UFH with tirofiban, and 69 (25%) (mean age 63 [SD ± 12] years) UFH only. Compared to the other strategies, a higher proportion of DM was observed in the enoxaparin-treated group (21%). No AST was associated with enoxaparin compared to 2 (1.8%) events in UFH with tirofiban and 1 (1.4%) in UFH only. The rate of severe bleeding events (BARC 2 and 3) was significantly lower in the enoxaparin-treated patients than in UFH with tirofiban (0 (0%) vs. 8 (7%), P = 0.01). 3 enoxaparin-treated patients needed switching to tirofiban as a bailout strategy due to distal vessel embolisation. Conclusions The novel 6-hour enoxaparin regimen is safe during PPCI and was associated with fewer bleeding events than UFH with tirofiban.
Poster No. 115 Switch the risk: from PDE5i to Riociguat in real world pulmonary hypertension
Authors: Mariana Martinho, Sofia Alegria, Filipa Ferreira, Rita Calé, Débora Repolho, Ana Rita Pereira, Alexandra Briosa, João Grade Santos, Bárbara Ferreira, Diogo Santos Cunha, Oliveira Baltazar, Nazar Ilchyshyn, João Mirinha Luz, Maria José Loureiro, Hélder Pereira
Journal: Cardiovascular Research (2022)

Abstract Introduction Switching from phosphodiesterase-5 inhibitors (PDE5i) to Riociguat is associated with increased efficacy in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Objective To show clinical efficacy of replacing PDE5i to Riociguat in a portuguese PH-dedicated centre. Methods Retrospective single-centre study of PAH and inoperable/persistent/recurrent CTEPH patients (pts) who switched vasodilator therapy. Parameters were stratified according to the 2022 PH guidelines and stratification as low/intermediate/high-risk PH followed the COMPERA registry, before switching, at 3–6 months of follow-up (FUP) and until the last clinical evaluation, balloon pulmonary angioplasty (BPA), heart transplant or death. Results Of 13 pts, 75.0% had CTEPH (4 pts had persistent disease after surgical endarterectomy), 16.7% had PAH and 1pt had mixed PAH/CTEPH. Mean age was 56.2 ± 16.3years and 83.3% were females. Mean time until switch was 33.5 ± 25.5 months. Previous therapy was: 33.3% Sildenafil, 41.7% Sildenafil/Bosentan and 25% Sildenafil/Bosentan/prostanoid. Before switching, 66.7% had intermediate and 33.3% low-risk PH; at a FUP of 4.4 ± 1.7 months, 8.3% had intermediate and 91.7% low-risk PH. There was a significant benefit in the COMPERA risk (1.50[1.33;1.62] vs. 1.22[1.09;1.40], P = 0.011). Long-term FUP was performed in 8 pts at 48.2 ± 35.6 months (death 1pt, transplant 1pt, BPA 3 pts). Medical treatment was Riociguat in 33.3%, Riociguat and Bosentan in 58.3%, and 1pt with Riociguat, Bosentan and Treprostinil. Clinical benefit was significant at long-term FUP when compared to the initial evaluation (1.22[1.09;1.40], P = 0.011), but not to the first FUP. Conclusion This study corroborates previous evidence regarding the vasodilator switch and also suggests that the treatment goal is maintained throughout long-term FUP.
Poster No. 018 Association of Cytochrome P450 2C19 polymorphisms with ischemic and bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention
Authors: Diona Gjermeni, Sofia Szabo, Viktoria Anfang, Hannah Theresa Vetter, Carina Juelch, Stefan Leggewie, David Hesselbarth, Dietmar Trenk, Daniel Duerschmied, Christoph B Olivier
Journal: Cardiovascular Research (2022)

Abstract Introduction Patients with atrial fibrillation (AF) after percutaneous coronary intervention (PCI) receive clopidogrel and direct oral anticoagulation. Platelet inhibition by clopidogrel varies according to CYP2C19 genotype. This study aimed to investigate the association of CYP2C19 genotype with antiplatelet effect of clopidogrel and ischemic and bleeding risk. Methods In this prospective observational study, patients with AF after PCI were grouped according to CYP2C19*2 and *17 diplotypes: *2/non-17* or *2/*2 as reduced metabolizers (RM), non-*2/*17 or *17/*17 as increased metabolizers (IM), and the remaining as normal metabolizers (NM). Platelet aggregation [U] was quantified by multiple electrode aggregometry. The primary outcome was time to death, myocardial infarction, or stroke (MACE) at 6 months. The secondary outcome was time to non-major clinically relevant (NMCR) or major bleedings. Results 156 patients were enrolled between May 2020 and May 2021. The median age was 78 years (interquartile range, IQR 71–82) and 109 (70%) were male. 31 patients (20%) were RM, 74 patients (47%) NM and 51 patients (33%) IM. The median ADP-induced platelet aggregation was not significantly different across these groups (RM: 12.8 [U]; NM: vs. 12.8 [U]; IM: 11.7 [U]; P = 0.39).The primary outcome occurred in 11 (7%) patients (RM: 1 [3%]; NM: 7 [9%]; IM 3[6%]). The secondary outcome occured in 3 RM (10%) and in 20 (16%) with NM + IM subtypes (HR 0.65 [95% CI 0.19–2.18], P = 0.485). Conclusion In this analysis reduced metabolizers were not at excessively increased risk of MACE. A trend for less bleeding was observed in carriers of loss-of-function allele CYP2C19*2.